A Phase I Study Of Sunitinib In Combination With S-1 And Cisplatin In Patients With Advanced Or Metastatic Gastric Cancer
Phase 1
20 Years
N/A
20 Years
N/A
Open (Enrolling)
Both
Stomach Neoplasms
Both
Stomach Neoplasms
Trial Information
A Phase I Study Of Sunitinib In Combination With S-1 And Cisplatin In Patients With Advanced Or Metastatic Gastric Cancer
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of gastric cancer
- Chemonaive patients
- Adequate organ function
Exclusion Criteria:
- Patients who meet the contra-indications of S-1 and Cisplatin.
- Prior chemotherapy failure patients
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
first cycle dose limiting toxicity (DLT)
Outcome Time Frame:
first cycle dose limiting toxicity (DLT)
Safety Issue:
Yes
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
Japan: Ministry of Health, Labor and Welfare
Study ID:
A6181127
NCT ID:
NCT00553696
Start Date:
November 2007
Completion Date:
September 2013
Related Keywords:
- Stomach Neoplasms
- chemotherapy
- combination
- Neoplasms
- Stomach Neoplasms
Name | Location |
|---|
